EDIT — Editas Medicine Share Price
0.000.00%
Last trade - 00:00- $451.47m
- $128.36m
- $78.12m
- 25
- 23
- 40
- 19
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.29 | ||
| Price to Tang. Book | 1.29 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 5.78 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -38.81% | ||
| Return on Equity | -43.17% | ||
| Operating Margin | -216.56% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 20.53 | 90.73 | 25.54 | 19.71 | 78.12 | 35.66 | 26.48 | 19.59% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Editas Medicine, Inc. is a clinical-stage genome editing company. The Company is focused on developing potentially transformative genomic medicines to treat a broad range of serious diseases. It has developed a proprietary gene editing platform based on CRISPR technology. CRISPR uses a protein- ribonucleic acid (RNA) complex composed of an enzyme, including either CRISPR associated protein 9 (Cas9) or Cas12a (CRISPR from Prevotella and Francisella 1, also known as Cpf1), bound to a guide ribonucleic acid (RNA) molecule designed to recognize a particular deoxyribonucleic acid (DNA) sequence. It is engaged in the development of vivo administered gene editing medicines, in which the medicine is injected or infused into the patient to edit the cells inside their body. Its lead program, reni-cel, is an experimental ex vivo gene-edited medicine to treat sickle cell disease (SCD), a severe inherited blood disease that causes premature death, and transfusion-dependent beta thalassemia (TDT).
Directors
- James Mullen CHM (62)
- Michelle Robertson CFO (54)
- Mark Shearman EVP (59)
- Bruce Eaton EVP
- Lisa Michaels EVP (56)
- Li Chi SVP
- Jessica Hopfield LED (56)
- Meeta Chatterjee IND (66)
- Bernadette Connaughton IND (63)
- Andrew Hirsch IND (50)
- Emma Reeve IND (60)
- David Scadden IND (68)
- Akshay Vaishnaw IND (59)
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- September 3rd, 2013
- Public Since
- February 3rd, 2016
- No. of Shareholders
- 19
- No. of Employees
- 265
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Global Select Market
- Shares in Issue
- 82,234,710
- Address
- 11 Hurley St, CAMBRIDGE, 02141-2110
- Web
- https://www.editasmedicine.com/
- Phone
- +1 6174019000
- Contact
- Cristi Barnett
- Auditors
- Ernst & Young LLP
Upcoming Events for EDIT
Editas Medicine Inc Annual Shareholders Meeting
Q2 2024 Editas Medicine Inc Earnings Release
Similar to EDIT
2Seventy Bio
NASDAQ Global Select Market
4D Molecular Therapeutics
NASDAQ Global Select Market
AbCellera Biologics
NASDAQ Global Select Market
AbSci
NASDAQ Global Select Market
Acadia Pharmaceuticals
NASDAQ Global Select Market
FAQ
What is the Editas Medicine share price?
As of Today at 19:07 UTC, shares in Editas Medicine are trading at $5.49. This share price information is delayed by 15 minutes.
How has the Editas Medicine share price performed this year?
Shares in Editas Medicine last closed at $5.49 and the price had moved by -28.24% over the past 365 days. In terms of relative price strength the Editas Medicine share price has underperformed the S&P500 Index by -40.28% over the past year.
What are the analyst and broker recommendations for Editas Medicine?
The overall consensus recommendation for Editas Medicine is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Editas Medicine dividend yield?
Editas Medicine does not currently pay a dividend.
Does Editas Medicine pay a dividend?
Editas Medicine does not currently pay a dividend.
When does Editas Medicine next pay dividends?
Editas Medicine does not currently pay a dividend.
How do I buy Editas Medicine shares?
To buy shares in Editas Medicine you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Editas Medicine?
As of the previous close price of $5.49, shares in Editas Medicine had a market capitalisation of $451.47m.
Where are Editas Medicine shares listed?
Here are the trading details for Editas Medicine:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: EDIT
What kind of share is Editas Medicine?
Based on an overall assessment of its quality, value and momentum Editas Medicine is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Editas Medicine share price forecast for 2024?
The analyst consensus target price for shares in Editas Medicine is $15.86. That is 188.89% above the last closing price of $5.49.
Analysts covering Editas Medicine currently have a consensus Earnings Per Share (EPS) forecast of -$2.66 for the next financial year.
What is the trend in the Editas Medicine share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Editas Medicine. Over the past six months, its share price has underperformed the S&P500 Index by -25.9%.
As of the last closing price of $5.49, shares in Editas Medicine were trading -34.64% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Editas Medicine PE Ratio?
The Editas Medicine PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $5.49.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Editas Medicine?
Editas Medicine's management team is headed by:
- James Mullen - CHM
- Michelle Robertson - CFO
- Mark Shearman - EVP
- Bruce Eaton - EVP
- Lisa Michaels - EVP
- Li Chi - SVP
- Jessica Hopfield - LED
- Meeta Chatterjee - IND
- Bernadette Connaughton - IND
- Andrew Hirsch - IND
- Emma Reeve - IND
- David Scadden - IND
- Akshay Vaishnaw - IND